Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Assets (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Assets data on record, last reported at $377.4 million in Q4 2025.

  • For Q4 2025, Assets fell 28.3% year-over-year to $377.4 million; the TTM value through Dec 2025 reached $377.4 million, down 28.3%, while the annual FY2025 figure was $377.4 million, 28.3% down from the prior year.
  • Assets reached $377.4 million in Q4 2025 per TRDA's latest filing, down from $412.9 million in the prior quarter.
  • Across five years, Assets topped out at $582.0 million in Q2 2024 and bottomed at $252.1 million in Q4 2022.
  • Average Assets over 4 years is $435.1 million, with a median of $472.4 million recorded in 2023.
  • Peak YoY movement for Assets: surged 86.15% in 2023, then fell 28.3% in 2025.
  • A 4-year view of Assets shows it stood at $252.1 million in 2022, then surged by 86.15% to $469.2 million in 2023, then increased by 12.18% to $526.3 million in 2024, then fell by 28.3% to $377.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $377.4 million in Q4 2025, $412.9 million in Q3 2025, and $448.8 million in Q2 2025.